The primary objective of this study is to determine whether primary PC is non-inferior to specialty PC for improving quality of life (QOL) in patients with AML.
This is a cluster randomized comparative effectiveness trial of primary palliative care (PC) versus specialty PC in 1150 patients with acute myeloid leukemia (AML) and their caregivers.
Hospitalized patients with high-risk Acute Myeloid Leukemia who are receiving either intensive chemotherapy or hypomethylating agents 1) Hospitalized patients (age > 18 years) with high-risk AML defined as one of the following: - Patients with new diagnosis > 60 years of age - An antecedent hematologic disorder - Therapy related-disease - Relapsed or primary refractory AML 2) Receiving treatment with either a) intensive chemotherapy (7+3) or modification of this regimen on a clinical trial, or a similar intensive regimen requiring prolonged hospitalization; or b) hypomethylating agents +/- additional agents or modification of this regimen on a clinical trial
Principal Investigator